Genexo and Enzymotec Sign Agreement to Commercialize CardiaBeat(TM) in Polish Consumer Health market

Genexo Pharmaceuticals, a private Polish pharmaceutical company and Enzymotec, an Israeli biotechnology company, have announced the signing of an agreement for the launch of CardiaBeatTM in the Polish market. The announcement follows a recent launch in India by the pharmaceutical company Elder.

CardiaBeatTM is an innovative proprietary ingredient which enhances the impact of plant sterols and omega-3 Fatty Acids, on cardiovascular disease (CVD) risk reduction. Earlier this year Enzymotec had announced its European Novel Food approval as well as the publication of its clinical study outcomes at the December 2006 issue of the American Journal of Clinical Nutrition.

"I am proud that Genexo has found CardiaBeatTM to be a complementary dietary supplement to the current drug line they have for CVD. The signing of this agreement and the recent Novel Food approval by the European heath authorities are important milestones in our sales and marketing strategy for CardiaBeat™ in Europe. We expect to finalize more strategic agreements before the end of this year" says Ms. Michal Haim-Bravman, Enzymotec’s marketing manager.

According to several market research pieces published in the last three years, the demand for dietary supplements in Poland is growing due to increasing willingness to self-medicate, as well as the awareness of CVD.

Genexo is a private Polish pharmaceutical company offering innovative products for the diagnosis, treatment and prevention of metabolic diseases including diabetes, hypercholesterolemia, and obesity. Key products include Glucosense® - biosensoric glucose monitoring system, Fosanic® - natural treatment for the metabolic syndrome and obesity, Glipid® - type 2 diabetes treatment. Well trained sales organization targets doctors and pharmacies in the territory of Poland.

Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional ingredients for dietary supplements, functional foods, clinical nutrition and advanced infant nutrition
Key products are: SharpPS™ line of products- phosphatidylserine based ingredients for cognitive improvement, InFat™ - structured fat for infant formulas , Krill Oil+ ™ and CardiaBeat™

Ms. Michal Haim-Bravman
Marketing Manager
Enzymotec Ltd.
E-mail: [email protected]
Fax: +972-4-6443799

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.